Becton Dickinson (BDX) Price Target Trimmed to $159 by Piper Sandler

Piper Sandler has reduced the price target for Becton, Dickinson and Company (BDX) from $170 to $159 while maintaining a Neutral rating. This adjustment was made on April 17, 2026, to align with management's revenue growth guidance. Additionally, RBC Capital Markets lowered its price target for BDX to $175 from $195, citing stable fundamentals in the MedTech sector. Both firms note that current sentiment around BDX may create investment opportunities, but they expect the stock to remain range-bound due to a lack of clear catalysts.